What does 99.4% purity on a C18 column actually tell me about an ecnoglutide vial?

Setup, so nobody has to ask: 99.4% · a C18 column · ecnoglutide.

I have read the primary source rather than the summary, which has left me with more questions.

I understand the headline. I do not understand the footnotes, and the footnotes look important.

What can I legitimately conclude from this figure?

Start by understanding what the detector is measuring and what that means about how the molecule needs to be prepared and handled before injection.

Mobile phase pH at the point where you inject must match the mobile phase pH at the start of the gradient, or the sample will not be focused at the column head.

Stated carefully, system suitability checks on replicate injections of a known standard establish whether the method was in control — if the peak area varies by more than two per cent between replicates, something is wrong.

I would caution against over-interpreting small differences between runs, because the noise floor of the method is larger than most people assume.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

Coupling the chromatography to mass spectrometry adds identity information but trades chromatographic quality for ionisation efficiency.

Trifluoroacetic acid at 0.1 per cent is the standard ion-pairing agent because it suppresses tailing by neutralising the basic residues, but it also suppresses mass spectrometry signal.

Detector linearity is why a heavily loaded peak can give false purity by compressing the main peak height while leaving impurity shoulders unchanged.

The selectivity of a reverse-phase separation depends on the hydrophobicity of the side-chain profile, which is why two peptides can co-elute even if they differ by a residue.

One qualification: the limit of detection on a reversed-phase HPLC is set by the noise on the baseline, which for these molecules is usually in the range of a tenth of one per cent or less, and anything smaller is not reproducibly detectable.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.

Put another way, method transfer between laboratories is almost impossible without full documentation, which is why two labs reporting the same preparation should expect disagreement.

Acetonitrile is the organic modifier of choice because it has a good UV cutoff, a reasonable viscosity and a refractive index that minimises baseline noise.

Worth noting that the achievable resolution depends on the chemistry of the molecule — some peptide sequences separate easily while others are notoriously difficult regardless of method.

Ask for the chromatogram and the system suitability data, not just the number.

The relevant detail is that the limit of this technique for these molecules is reaching a point where small improvements require proportionally large investments in method development.

Wider-pore phases — 300 Angstrom rather than 100 Angstrom — have faster mass transfer and narrower peaks for peptides above three kilodaltons, which is almost every peptide you will see.

Peptide impurities from solid-phase synthesis include deletion sequences, truncations from premature cleavage, racemised residues from epimerisation and oxidised variants, each of which may have different chromatographic behaviour.

The caveat is that HPLC is a purity technique and says almost nothing about whether the main peak is actually your target compound — that is why identity confirmation from mass spectrometry or peptide mapping matters.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.